DEA Moves to Ban 7-OH: What the Synthetic Kratom Crackdown Means for People in Recovery

On July 1, 2026, the U.S. Drug Enforcement Administration filed two Notices of Intent to temporarily place 7-hydroxymitragynine — the concentrated compound sold as “7-OH” — into Schedule I of the Controlled Substances Act. The action also covers a group of related synthetic analogs: mitragynine pseudoindoxyl, MGM-15, and MGM-16.

If stopping is the immediate concern, start with our step-by-step kratom & 7-OH detox guide — symptoms, timeline, and safe options.

For the millions of Americans who have bought 7-OH tablets, gummies, and shots at gas stations and smoke shops believing they were purchasing a mild herbal supplement, this is a turning point. Federal regulators are now treating 7-OH as what the FDA has called it since 2025: an addictive opioid.

If you or someone you love has become dependent on 7-OH or another opioid, this page explains what the scheduling action means, why 7-OH is more dangerous than most users realize, and what treatment pathways exist — including ibogaine, which has a growing evidence base for interrupting opioid dependence.

If you’re dealing with opioid dependence right now, you don’t have to wait for the legal situation to settle. Request a consultation or call (866) 435-7057 to talk through your options.

Medical Disclaimer: This page is educational only and does not constitute medical advice. Opioid withdrawal can be dangerous. Do not stop using opioids abruptly without medical guidance. Always work with a qualified medical provider.

What Actually Happened on July 1, 2026

The DEA’s action was not a surprise. The FDA formally recommended scheduling concentrated 7-OH products in July 2025, and FDA Commissioner Marty Makary has repeatedly described 7-OH as a novel opioid threat — one the agency has moved to restrict and, in some cases, physically seize from distributors.

The two Notices of Intent filed on July 1 do two things:

• The first targets 7-hydroxymitragynine above a specified concentration threshold — the concentrated, chemically enhanced products, not raw kratom leaf.
• The second moves related synthetic analogs (mitragynine pseudoindoxyl, MGM-15, and MGM-16) toward Schedule I.

A temporary scheduling order can take effect relatively quickly, though a permanent placement still runs through the standard rulemaking process, including a public-comment period. The practical message to consumers is clear: the federal government now classifies concentrated 7-OH alongside heroin and other Schedule I opioids.

One distinction matters here, and the American Kratom Association has pushed hard on it: 7-OH is not the same as natural whole-leaf kratom. Raw kratom leaf contains only trace amounts of 7-hydroxymitragynine. The products under scrutiny are concentrated or semi-synthetic — engineered to deliver 7-OH at levels many times higher than anything that occurs in the plant. Separately, in June 2026 the NIH cleared the way to study natural kratom as a potential treatment for opioid use disorder, underscoring that the regulatory concern is aimed at the concentrated synthetic products, not the leaf.

Why 7-OH Is More Dangerous Than Its Marketing Suggests

7-hydroxymitragynine is a potent mu-opioid receptor agonist. In plain terms, it acts on the same brain receptors as morphine, oxycodone, and heroin. That is the mechanism behind both its pain-relieving effects and its capacity to create physical dependence.

Because 7-OH was sold openly and marketed as a natural wellness product, many people who now find themselves dependent never thought of themselves as using an opioid at all. They report the same pattern opioid clinicians know well: escalating doses, withdrawal symptoms between uses, and difficulty stopping despite wanting to.

This is the population the scheduling action will most immediately affect. When these products come off store shelves, people who are physically dependent face withdrawal — and the question of what comes next.

A note on SR-17018 and the wider research-chemical problem

7-OH is one piece of a larger pattern. Novel opioid research chemicals — compounds like SR-17018, an experimental biased mu-opioid agonist first described by Scripps Research in 2017 — continue to circulate in gray markets despite never being approved for human use and never completing human trials. SR-17018 is not FDA-approved and has not been formally scheduled, though federal prosecutors can treat unapproved opioids like it as controlled substances under the Federal Analogue Act. The 7-OH action signals that regulators are watching this entire category of unapproved synthetic opioids closely.

What Treatment Options Exist for Opioid Dependence

For anyone dependent on 7-OH or any opioid, the evidence-based treatment landscape includes several distinct pathways. The right one depends on the individual, the severity of dependence, and personal goals.

Medication-assisted treatment (MAT). Buprenorphine (Suboxone) and methadone are the standard of care for opioid use disorder and reduce overdose risk substantially. These are legal, widely available, and the first option most clinicians recommend.

Residential and outpatient rehabilitation. Structured programs that combine detox, counseling, and relapse prevention.

Ibogaine. For a subset of patients — particularly those who have cycled through conventional treatment without lasting results — ibogaine has drawn serious attention. Ibogaine is a naturally occurring compound that acts on multiple receptor systems involved in addiction and has been observed to interrupt opioid withdrawal and craving in a single treatment. It has received FDA Breakthrough Therapy Designation for further research, and a 2024 Stanford study led by Dr. Nolan Williams documented significant reductions in PTSD, depression, and functional disability in veterans treated with ibogaine in Mexico.

Ibogaine is a Schedule I substance in the United States, so patients travel to licensed clinics abroad — most commonly in Mexico, where it is legal and administered under medical supervision. It carries real cardiac risks and is not appropriate for everyone, which is why medical screening is essential. Our Ibogaine Safety Guide covers cardiac screening, medication tapers, and contraindications in detail.

How Psychedelic Connect Helps

Psychedelic Connect is a patient advisory service. We connect people seeking treatment with vetted ibogaine and 5-MeO-DMT clinics, and we help patients understand whether a given pathway is appropriate for their situation before they commit to anything.

If you’re dependent on 7-OH, an opioid, or another substance and you’re trying to figure out what to do next, we can help you think it through. We only recommend clinics that meet our clinical vetting standards — required cardiac screening, on-site physicians, and documented safety protocols.

Request your consultation or call (866) 435-7057. If you’re in immediate crisis, contact the SAMHSA National Helpline at 1-800-662-HELP (4357) or call 988 for the Suicide and Crisis Lifeline.

Frequently Asked Questions

Q: Is 7-OH banned now? As of July 2026, the DEA has filed Notices of Intent to temporarily schedule concentrated 7-OH and related synthetic analogs as Schedule I. A temporary order can take effect relatively quickly, but a permanent ban still runs through the standard federal rulemaking process, which includes a public-comment period. Several states, including Tennessee, already restrict 7-OH under their own laws.

Q: Is 7-OH the same as kratom? No. Natural whole-leaf kratom contains only trace amounts of 7-hydroxymitragynine. The products facing federal scheduling are concentrated or semi-synthetic 7-OH products with levels far higher than anything in the raw plant. In June 2026, the NIH cleared the way to study natural kratom as a potential treatment for opioid use disorder.

Q: Is 7-OH an opioid? Yes. 7-hydroxymitragynine is a mu-opioid receptor agonist — it acts on the same brain receptors as morphine and heroin. The FDA has classified it as an addictive opioid.

Q: What happens if I’m dependent on 7-OH and it’s taken off shelves? People who are physically dependent on 7-OH can experience opioid withdrawal when they stop. Do not stop abruptly without medical guidance. Evidence-based options include medication-assisted treatment (buprenorphine or methadone), residential rehabilitation, and — for some patients — ibogaine. Speak with a medical provider about the safest path for your situation.

Q: Can ibogaine help with 7-OH dependence? Ibogaine has been observed to interrupt opioid withdrawal and craving across opioid classes, and 7-OH acts as an opioid. However, ibogaine carries cardiac risks and requires thorough medical screening, and patients on long-acting opioids need a supervised taper first. Whether it’s appropriate depends on your health history. Our advisory service can help you evaluate the option — call (866) 435-7057.

Q: Was SR-17018 also banned? No. SR-17018 is an unapproved experimental opioid research chemical that has not been formally scheduled as of July 2026, though it can be treated as a controlled substance under the Federal Analogue Act. It was not part of the July 1, 2026 DEA action, which targeted concentrated 7-OH and related analogs.